Reports Q3 Cash totaled C$39M as of December 31; Cash-based operating expenses totaled C$17.1M n for the quarter ended December 31 compared to C$11.1M in the prior year quarter.Cash flows used in operating activities were C$19M for the quarter ended December 31 compared to C$10.8M in the same period last year.”During the past three months, we have continued to make exciting progress with positive topline data from our CYB003 and DMT programs,” said Doug Drysdale, Chief Executive Officer of Cybin. “The data collected from our clinical trials forms the foundation of our next set of value-creating milestones, as we advance our key programs this year. For CYB003, the three-month Phase 2 efficacy data is expected in Q1 and will provide insights into the durability of treatment effect in MDD. Promising outcomes, such as a 79% remission from depression at 6 weeks in our Phase 2 CYB003 trial, and important safety and dosing findings in our Phase 1 dDMT studies, validate our path forward. Plans are underway to initiate a Phase 3 multisite trial of CYB003 for MDD, and with FDA clearance, we are progressing to a Phase 2a study of CYB004 for the treatment of GAD. We are proud of the rapid progress we have made and look forward to the important work ahead of us. We are encouraged by the positive findings across our clinical-stage programs to date and believe we are well on our way to providing more effective and patient-friendly treatment alternatives for a multitude of mental health disorders,” concluded Drysdale. Cash totaled C$39.M as of December 31.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYBN:
- CYBN Earnings this Week: How Will it Perform?
- Cybin granted two additional patents in Japan
- Here’s What You Missed in Cannabis, Psychedelics This Week
- FDA clears Cybin IND application for CYB004 for GAD, begins Phase 2a in Q1
- Cybin: IM dosing of SPL028 produced robust, short-duration psychedelic effects
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue